Trials / Completed
CompletedNCT03443674
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
A Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Peritoneal Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Clover Biopharmaceuticals AUS Pty · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered twice weekly for 2 weeks via IP bolus injection for the treatment of patients with peritoneal malignancies, including but not limited to peritoneal carcinomatosis, malignant ascites, pseudomyxoma peritonei, and peritoneal mesothelioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCB-313 | Lyophilized powder in a single-use vial |
Timeline
- Start date
- 2018-06-18
- Primary completion
- 2021-05-30
- Completion
- 2021-08-26
- First posted
- 2018-02-23
- Last updated
- 2021-10-19
Locations
5 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT03443674. Inclusion in this directory is not an endorsement.